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Abstract
Introduction: APOE is the strongest risk gene for sporadic Alzheimer’s disease (AD) so far. Recent genome wide
association studies found links for sporadic AD with CLU and CR1 involved in Ab clearance, and PICALM affecting
intracellular trafficking.
Methods: We investigated the associations of senile plaques (SP) and neurofibrillary tangles (NFT) with the
proposed risk genes and APOE, in the Tampere Autopsy Study (TASTY) series (603 cases), a sample of the general
population (0 to 97 yrs), who died out-of-hospital.
Results: Age and the APOEε4 allele associated strongly with all phenotypes of SP, as expected. In age and APOEε4
adjusted analyses, compared to the most common homozygous genotype, burnt out SP were more common
among carriers of the C-allele of CLU, whereas the T-allele of PICALM and C-allele of CR1 were linked with lower SP
coverage. We found no significant associations between any of the genetic variants and NFT.
Conclusions: Marginal effects from CLU, CR1 and PICALM suggest that these genes have minimal effects on the
development of AD lesions.
Introduction
Alzheimer’s disease (AD) is the most common form of
dementia in Western society and is, and will continue to
be, a burden on health systems in the future as the
population ages. Age is the largest risk factor for the
disease, with higher incidences in older populations
[1,2].
Identification of genes related to sporadic AD risk has
been slow with study groups isolating only one strongly
associated gene: APOE [3,4]. The epsilon 4 allele of apo-
lipoprotein E (APOEε4) provides odds ratios (ORs) of
between 3 and 25 [5,6] for disease association. APOEε4
is suspected to have a lower effectiveness at transporting
cholesterol and is not as efficient at repairing neuronal
damage as APOEε3 [7]. One or even two copies of the
allele, however, are not sufficient to cause the disease, as
many carriers of two ε4 alleles do not develop AD [5].
Studies aiming to detect genes associated with disease
risk have used heterogeneous AD cohorts and ascer-
tained few polymorphisms with only a minor impact on
disease incidence. One of the problems is to distinguish
between pure AD, vascular dementia and other demen-
tia types in clinical cohorts [8-10]. The only consistent
and currently accepted method for confirming AD is
with post-mortem assessment of the neuropathological
lesions neurofibrillary tangles (NFT) and senile plaques
(SP) [11-14].
Demented individuals do not always exhibit large
enough numbers of SP to warrant an AD diagnosis [15]
and NFT and SP are both relatively common in the gen-
eral population [16-19]. Furthermore, these lesions do
not provide a clear-cut explanation as to the cause of
AD, with different theories advocating amyloid beta
(Ab) accumulation [12,20] or hyperphosphorylated
NFT-causing tau protein [21] as the underlying initiat-
ing mechanisms that trigger the disease.
Two recent extensive genome-wide association studies
(GWAS), comprising 12,000 probable AD cases and
18,000 age-matched non-demented controls [22,23],
revealed three new candidates for genetic risk of devel-
oping late onset or sporadic AD: CLU, CR1 and
PICALM. Phosphatidylinositol-binding clathrin assembly
protein (PICALM) is involved in synaptic neurotrans-
mitter release and intracellular trafficking [24-26], whilst
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main receptor of complement C3b protein, binds Ab
and thus may promote clearance [27-30]. Clusterin
(CLU, and also known as ApoJ), was replicated indepen-
dently in the two studies and is thought to bind and
remove Ab from the brain, as well as assist in re-entry
of Ab [31-34].
We have previously shown th a ta sm a n ya so n e - t h i r d
of non-demented individuals in an autopsy series-based
sample carry SP and more than 40% NFT, with strong
age dependence [16]. This suggests that in clinical study
series, non-demented control patients may not be free
of AD-related neuropathological lesions. Utilising this
same cohort, we aimed to investigate whether SP and
NFT are associated with any of the recently identified
GWAS single nucleotide polymorphisms (SNPs); CLU,
CR1 and PICALM to examine their involvement in the
development of these brain lesions.
Materials and methods
Autopsy series
The Tampere Autopsy Study (TASTY) cohort consisted
of 603 autopsy cases, of which the majority died out-of-
hospital within Tampere, Finland and surroundings, col-
lected during the years 2002 to 2004 (described in detail
elsewhere [16]). The study was approved by the Board
of Medicolegal Affairs of Finland. Females within the
cohort accounted for 35.8% and the ages for the entire
series ranged from 0 to 97, with an average of 63 years
(59 years for males and 68 years for females). Of the
cases, 6 (1%) had a clinical AD diagnosis, 16 (2.7%)
undefined dementia, 10 (1.7%) had memory disorders
and 1 (0.2%) had Parkinson’s disease prior to death
(according to available hospital records and next of kin
reports). In some cases it was impossible to obtain all
variables due to technical difficulties and sample
damage.
Alzheimer-related lesion measurements
SP and NFT staining and measures have be portrayed
previously [16]. Briefly, the Bielschowsky argyrophilic sil-
ver impregnation method was performed on samples
and measured by two researchers to acquire SP (neocor-
tex) and NFT (hippocampus) counts. Each area was
screened to find the highest density of SP (neocortical
area at 100 × magnification) and NFT (hippocampus -
CA1 area at 200 × magnification) and then scored using
a square microscopic grid (SP - 100 intersections cover-
ing 1 mm
2, NFT - four to six random columns), before
creating an average percentage of coverage (SP) or aver-
age number in 1 mm
2 (NFT). Bielschowsky staining was
highly correlated with Amyloid beta (Ab) staining (anti-
body from Cell Signaling Technology, Danvers, MA,
USA; concentration 1:150), which was used to verify our
previous results [16], and used the same cortical cover-
age of SP method. SP and NFT variables included the
following categorisations as measured by a neuropathol-
ogist: SP (No, Yes), SP type (No Plaques, Diffuse, Primi-
tive, Classic, Burnt Out), SP type 2 (No Plaques,
Non-neuritic SP, Neuritic SP), NFT (No, Yes), where
reference groups were those with ‘No SP’ or ‘No NFT’
and those with either brain lesion were considered
‘affected’. Semi-quantitative data for SP utilised the cate-
gories ‘no’, ‘sparse’, ‘moderate’ and ‘frequent’ SP.
Genotyping
The ABI Prism 7900HT Sequence Detection System
used 1 μl DNA with PCR primers (Applied Biosystems,
Espoo, Finland) for rs11136000 (CLU), rs1408077 (CR1)
and rs3851179 (PICALM). All SNPs were in Hardy-
Weinberg equilibrium and genotyping confirmed using
SDS version 2.2 (Applied Biosystems). Genotyping for
APOE has been previously described [16]. Genotyping
for the polymorphisms of CLU, CR1 and PICALM were
successful for 94%, 97% and 97% of the TASTY cases,
respectively.
Statistics
Logistic regression analyses, with continuous age and
APOEε4 carriership as covariates (where possible), were
used with SPSS (version 14.0 for Windows; SPSS
Finland Oy, Espoo, Finland) to determine associations
between the SNPs and AD-related neuropathological
lesions. For all SNPs, the most common homozygous
genotype was used as the reference group. As previously
mentioned, those unaffected by SP or NFT were consid-
ered the reference group for the brain lesion categories.
When analysing with the cohort split by age groups, the
following categories were used: 0 to 49 years, 50 to 59
years, 60 to 69 years, 70 to 79 years, 80+ years, with the
youngest group (0 to 49 years) considered the reference
group with respect to age, in analyses. The cohort was
also split by gender, where mentioned.
Results
Autopsy series characteristics
The Tampere Autopsy Series (TASTY) (n = 603) com-
prises consecutive autopsies on males and females aged
0 to 97 years that lived outside institutions or hospitals
(see Table 1). Females were on average 10 years older
than males, but males were more likely to have SP com-
pared to females (odds ratio (OR) 2.15, P < 0.0001, 95%
confidence intervals (CI) 1.49 to 3.11). When age was
divided into five equal-sized groups, each age group was
consistently more likely to have SP compared to the
youngest group, with each association also highly statis-
tically significant (see Table 2). This was also true for
NFT prevalence (see Table 2), with females more likely
Kok et al. Alzheimer’s Research & Therapy 2011, 3:12
http://alzres.com/content/3/2/12
Page 2 of 9than males to have NFT (OR 2.18, P < 0.0001, CI 1.49
to 3.18).
APOE, CLU, CR1 and PICALM associations with SP
As expected, APOEε4 carriership was significantly asso-
ciated with increased risk of having SP (OR 2.52, P <
0.0001, CI 1.72 to 3.68); having both non-neuritic (OR
2.42, P = 0.003, CI 1.36 to 4.29) and neuritic SP (OR
2.58, P < 0.0001, CI 1.66 to 4.02) compared to no SP;
and having primitive (OR 2.53, P = 0.010, CI 1.25 to
5.10), classic (OR 2.52, P < 0.0001, CI 1.54 to 4.13) and
burnt out SP (OR 2.77, P = 0.014, CI 1.22 to 6.27) com-
p a r e dt on oS P ,w h e ne v a l u a t e da g a i n s tn o nε4 carriers
(see Table 3). Results showed similar trends when the
cohort was split by gender (data not shown).
APOEε4 carriers, compared to ε3-ε3 carriers, were sig-
nificantly associated with an increased risk of having SP in
all age groups except the youngest and oldest (Figure 1).
There was a trend of age-related increases in SP, especially
of the neuritic type, across all studied genotypes. The
APOEε2 carrier group was too small to investigate sup-
posed protective effects, although previously published
results suggest tendencies towards protection [16]. In
APOEε4 adjusted analyses, 80+ year old carriers of the
rare TT genotype of PICALM had a significantly lower
incidence of SP compared to the common CC carriers
(OR 0.18, P = 0.025, CI 0.04 to 0.81) (see Figure 1). This
association was not seen among younger age groups.
There were no significant associations between genotypes
of CLU and CR1 and SP prevalence.
Grouping the rare homozygote and heterozygotes
versus the common homozygotes for the SNPs uncov-
ered statistically significant associations between the T
allele of PICALM and SP (OR 0.62, P = 0.028, CI 0.41
to 0.95, versus CC genotype). When we divided the SP
into diffuse, primitive, classic and burnt out pheno-
types (to investigate the particular phases of the SP life
cycle), we found that the rare C allele of CLU was sig-
nificantly associated with the presence of late stage SP
(OR 4.4, P = 0.004, CI 1.61 to 12.2) compared to the
common TT genotype (Table 3). In that setting, the
statistically significant association of the PICALM T
allele was lost.
Table 1 TASTY cohort characteristics
Age (years) 0 to 97 62.67
Males 388 64.3%
Cause of Death
Disease 59.1%
Accident 26.8%
Suicide 11.8%
Homicide 0.5%
Unknown 1.5%
Dementia Status
AD 6 1%
Dementia 16 2.7%
Memory Problems 10 1.7%
Parkinson’s Disease 1 0.2%
SP 172 31.1%
NFT 204 42.1%
SP type
Diffuse 21 3.7%
Primitive 35 6.2%
Classic 83 14.7%
Burnt Out 25 4.4%
SP type 2
Non-neuritic SP 56 9.9%
Neuritic SP 108 19.1%
Semi quantitative SP coverage
Sparse SP 90 16.2%
Moderate SP 62 11.2%
Frequent SP 32 5.8%
APOEε4 carriership 187 31.1%
Table 2 Senile plaque and neurofibrillary tangle prevalence in the TASTY cohort by age group
Age group (years) Total Affected (%) P-value Odds Ratio 95% Confidence Interval
Senile plaques
0 to 49 119 7 5.9 Ref - -
50 to 59 101 17 16.8 0.013 3.24 1.29 to 8.16
60 to 69 89 21 23.6 0.001 4.94 1.99 to 12.24
70 to 79 130 56 43.1 <0.0001 12.11 5.23 to 28.01
80+ 114 71 62.3 <0.0001 26.42 11.27 to 61.96
Neurofibrillary tangles
0 to 49 103 13 12.6 Ref - -
50 to 59 90 28 31.1 0.002 3.13 1.50 to 6.51
60 to 69 82 23 28.0 0.010 2.70 1.27 to 5.74
70 to 79 109 62 56.9 <0.0001 9.13 4.56 to 18.28
80+ 100 78 78.0 <0.0001 24.55 11.60 to 51.95
Those ‘Affected’ refers to those cases in the TASTY cohort that are affected by senile plaques or neurofibrillary tangles, accordingly.
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Page 3 of 9Table 3 Association of senile plaque type with APOE, CLU, CR1 and PICALM genotypes
SP Diffuse Primitive Classic Burnt out
Valid
N
SP OR (95% CI) P-value Diffuse OR (95% CI) P-
value
Primitive OR (95% CI) P-
value
Classic OR (95% CI) P-value Burnt
out
OR (95% CI) P-
value
APOEε4-
1 388 88
(22.7)
- - 12 (3.1) - - 19 (4.9) - - 44
(11.3)
- - 13 (3.4) - -
APOEε4+ 174 74
(42.5)
3.2 (2.05 to
4.90)
<0.0001* 9 (5.2) 2.4 (0.97 to
5.86)
0.059 16 (9.2) 2.8 (1.37 to
5.74)
0.005* 37
(21.3)
3.2 (1.83 to
5.48)
<0.0001* 12 (6.9) 3.8 (1.56 to
9.01)
0.003*
CLU TT
2 336 89
(26.5)
- - 13 (3.9) - - 22 (6.5) - - 48
(14.3)
- - 6 (1.8) - -
CLU C+ 194 60
(30.9)
1.1 (0.73 to
1.76)
0.570 6 (3.1) 0.79 (0.29 to
2.14)
0.641 11 (5.7) 0.9 (0.39 to
1.84)
0.680 27
(13.9)
0.99 (0.56 to
1.77)
0.988 16 (8.2) 4.4 (1.61 to
12.2)
0.004*
CR1 AA
2 186 56
(30.1)
- - 8 (4.3) - - 9 (4.8) - - 28
(15.1)
- - 11 (5.9) - -
CR1 C+ 361 102
(28.3)
0.9 (0.62 to
1.54)
0.924 12 (3.3) 0.71 (0.28 to
1.80)
0.475 24 (6.6) 1.2 (0.55 to
2.77)
0.611 53
(14.7)
0.85 (0.48 to
1.49)
0.572 13 (3.6) 0.57 (0.24 to
1.40)
0.221
PICALM
CC
2
219 71
(32.4)
- - 7 (3.2) - - 19 (8.7) - - 37
(16.9)
- - 8 (3.7) - -
PICALM T
+
327 87
(26.6)
0.6 (0.41 to
0.95)
0.028* 12 (3.7) 1.09 (0.42 to
2.84)
0.864 16 (4.9) 0.5 (0.26 to
1.09)
0.086 42
(12.8)
0.73 (0.42 to
1.25)
0.253 17 (5.2) 1.36 (0.55 to
3.39)
0.508
Abbreviations: APOE , Apolipoprotein E; CI, confidence intervals; CLU , Clusterin; CR1, complement component (3b/4b) receptor 1; N, number of cases; OR, odds ratio; PICALM, phosphatidylinositol-binding clathrin
assembly protein; SP, senile plaques; No SP was the reference group. Numbers in brackets are percentages, unless otherwise stated. In some cases it was impossible to obtain all variables due to technical
difficulties and sample damage.
* Denotes statistically significant values.
1 Denotes reference group used for statistical analyses. Age was used as a covariate.
2 Denotes most common homozygous genotype and used as the reference group for statistical analyses. APOEε4 carriership and age were used as covariates.
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9APOE, CLU, CR1 and PICALM associations with SP
frequency
When analyses were performed with SP frequency as the
dependent variable, APOEε4 carriership was again found
to be highly significantly associated with increasing SP
coverage, compared to ε3-ε3 carriers (see Table 4).
PICALM TC genotypes (versus CC genotype) were signif-
icantly less likely to have moderate SP compared to no
SP (OR 0.42, P = 0.012, CI 0.21 to 0.83), whilst CR1 CC
genotype carriers (compared to AA genotype) were more
likely to have sparse SP than no SP (OR 2.1, P = 0.048,
CI 1.01 to 4.43).
When we grouped the rare homozygote and heterozy-
gotes together versus the common homozygotes (Table
4), significance was lost for CR1,h o w e v e rPICALM T
allele carriers remained less likely to have coverage of
SP versus no SP compared to CC genotype, however
again statistical significance was only reached for mod-
erate SP (OR 0.43, P = 0.010, CI 0.23 to 0.82).
Associations with gender
Reanalysing the significant associations with the cohort
split by gender gave similar results (data not shown),
with females generally more strongly associated, most
likely due to their older age. No further significant asso-
ciations were uncovered.
Associations with Ab staining
A subpopulation of the cohort were assessed for associa-
tions with immunohistochemical staining (n =1 5 2 ) .
None of the newly identified SNPs were statistically sig-
nificantly associated with Ab staining, as seen in Figure 2.
APOEε4 carriership, however, was significantly associated
with higher cortical coverage of Ab staining (P < 0.0001).
Discussion
AD is the most common form of dementia, but to date
its aetiology has remained elusive, despite intensive
research. The proposed causes of AD relate to neuro-
pathological findings post-mortem, which is the only
way to definitively confirm a patient’s diagnosis [11-14].
Diagnosis of the first AD patient, back in 1906, revealed
large numbers of SP and NFT; however, although new
treatments aimed at reversing the disease by reducing
SP have proven successful, they have been without
improvements in cognitive abilities of patients [35].
Figure 1 Senile plaque prevalence by age and genotype (APOE, CLU, CR1 and PICALM). CI = confidence interval; OR = odds ratio.
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Page 5 of 9Table 4 Association of senile plaque coverage with APOE, CLU, CR1 and PICALM genotypes
Sparse SP Moderate SP Frequent SP
Valid N No SP Sparse SP OR (95% CI) P-value Moderate SP OR (95% CI) P-value Frequent SP OR (95% CI) P-value
APOEε4-
1 378 281 (74.3) 51 (13.5) - - 29 (7.7) - - 17 (4.5) - -
APOEε4+ 174 89 (51.1) 39 (22.4) 2.86 (1.73 to 4.74) <0.0001* 32 (18.4) 5.32 (2.81 to 10.06) <0.0001* 14 (8.0) 3.97 (1.76 to 8.94) 0.001*
CLU TT
2 329 227 (69.0) 48 (14.6) - - 33 (10.0) - - 21 (6.4) - -
CLU C+ 192 123 (64.1) 37 (19.3) 1.26 (0.76 to 2.09) 0.378 23 (12.0) 1.06 (0.55 to 2.03) 0.873 9 (4.7) 0.68 (0.29 to 1.63) 0.391
CR1 AA
2 182 125 (68.7) 22 (12.1) - - 21 (11.5) - - 14 (7.7) - -
CR1 C+ 355 234 (65.9) 65 (18.3) 1.48 (0.85 to 2.58) 0.167 38 (10.7) 0.92 (0.48 to 1.78) 0.807 18 (5.1) 0.62 (0.28 to 1.38) 0.242
PICALM CC
2 217 136 (62.7) 33 (15.2) - - 32 (14.7) - - 16 (7.4) - -
PICALM T+ 319 222 (69.6) 54 (16.9) 0.97 (0.58 to 1.60) 0.898 27 (8.5) 0.43 (0.23 to 0.82) 0.010* 16 (5.0) 0.58 (0.26 to 1.26) 0.169
Abbreviations: APOE , Apolipoprotein E; CI, confidence intervals; CLU , Clusterin; CR1, complement component (3b/4b) receptor 1; N, number of cases; OR, odds ratio; PICALM, phosphatidylinositol-binding clathrin
assembly protein; SP, senile plaques. No SP was the reference group. Numbers in brackets are percentages, unless otherwise stated. In some cases it was impossible to obtain all variables due to technical difficulties
and sample damage.
* Denotes statistically significant values.
1 Denotes reference group used for statistical analyses. Age was used as a covariate.
2 Denotes most common homozygous genotype and used as the reference group for statistical analyses. APOEε4 carriership and age were used as covariates.
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9Furthermore, studies have shown cognitively normal
elderly can also have large numbers of these brain
lesions [16-19] and not all AD cases have the required
amounts to corroborate cognitive dysfunction [15].
Genome wide association studies (GWAS) investigat-
ing AD have in the past not been powerful enough to
reveal anything except APOE. Two recent large GWAS
[22,23], however, collectively investigated over 30,000
individuals (with almost 12,000 probable AD cases) and
examined around 500,000 SNPs that may influence AD
risk.
We recently showed that SP and NFT were surpris-
ingly common in a non-demented autopsy series, which
represents the closest model to a population sample and
that the occurrence of SP, but not NFT, was strongly
affected by the APOEε4 allele, regardless of age [16].
Because of the GWAS’ discoveries of three potential
new candidates for AD risk, we decided to look at their
associations with the neuropathological lesions SP and
NFT in our cohort to investigate their involvement in
the development of these brain lesions.
SP associated with both age and gender, and the
APOEε4 allele was highly associated with SP in many of
our analyses. Additional analyses showed that the
APOEε4 associations were extremely robust in the
TASTY series, thus validating our cohort’s ability to
detect associations with the measured brain lesions.
However, whilst NFT were found to associate with age
and gender, they were not associated with any of the
SNPs investigated. The strong association seen between
males and SP prevalence, and females and NFT occur-
r e n c em a yb eac o n f o u n d i n gf a c t o r ,d u et ot h eo l d e r
average age of females in the cohort. Additionally, our
cohort may over-represent early and violent deaths;
however, all cases were included to best represent a
population-based investigation.
Figure 2 Boxplots of cortical SP coverage (%) according to Ab staining and genotype (APOE, CLU, CR1 and PICALM).
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CR1 and PICALM) would also associate with SP, as they
are involved in AD pathways and most likely would be
associated with the development of brain lesions
[24-34]. Our results indicate that we did not find as
many robust correlations as for APOE.
Genetic variants of CLU, PICALM and CR1 genes
were associated with SP and remained so with the inclu-
sion of APOEε4 carriers and age as covariates. The
appearance of an increased risk for CLU C carriers ver-
s u sT Ti su n u s u a li nt h a ti to n l ya p p l i e sf o rB u r n tO u t
SP - a group in the cohort that is relatively small and
are majority females. This suggests that the effect of
CLU could be on the later stages of SP development
and related to removal of Ab [31-34] being reduced in
efficiency.
The PICALM T allele appears to have a protective
effect on SP prevalence, true also for TT genotypes, ver-
sus CC genotypes in the oldest age group. This may be
due to more efficient intracellular trafficking and clear-
up of Ab, or the components or pathways that induce
Ab build-up or production [24-27]. The protective effect
of the T carriers was seen also for SP coverage; however,
it was only significant for moderate SP.
CR1 CC genotype carriers were associated with an
increased risk of having sparse compared to no SP; how-
ever, the trend was not consistent for increasing cover-
age of SP (data not shown), which was also true for the
analysis grouping the rare homozygote with the hetero-
zygotes. This suggests the effect of CR1 is complex and
not as straight-forward as increasing SP risk and
requires further investigation.
The lack of robust and numerous associations with the
GWAS SNPs and brain lesions, alongside the strong
APOEε4 results, questions the involvement of SP in AD
pathology. It may be a coincidence that SP are found in AD
brains with evidence suggesting that they may be a part of
normal aging [16,17]. In light of this, SP treatments have so
far failed to improve patients’ cognitive abilities [35] and
current theories are moving away from SP and suggest
soluble oligomeric Ab m a yb et h ec u l p r i ti nA D[ 3 6 - 3 9 ] .
The scarcity of associations may be due to the small num-
ber of cases with SP within the TASTY series (31.1%),
resulting in low power; however, we have a 600 case-strong
cohort, which revealed strong associations between APOE
w i t hS P .I tm a ya l s ob ed u et ot h el o ws t r e n g t ho ft h e s e
prior associations in the original studies, which should be
investigated in future cohorts of a similar nature.
Some may question the use of an autopsy series to
investigate an age-dependent illness such as AD; how-
ever, the TASTY cohort provides a unique view into the
early midlife prevalence of well-defined neuropathologi-
cal lesions, showing their common prevalence.
Conclusions
We have an interesting window into the development of
neuropathological lesions and their associations with
AD-risk genes in the general population, and as far as
w ek n o w ,t h i si st h ef i r s ts t u d yo fi t sk i n d .S Pw e r e
found to associate with age, gender, and APOEε4, but
not consistently with CLU, CR1 or PICALM, suggesting
that these SNPs most likely do not affect the develop-
ment of the studied neuropathological lesions. Further
studies should replicate these findings in a larger
autopsy series of the same kind, both with and without
AD cases, to define the occurrence of these neuropatho-
logical lesions within the context of normal aging.
Our results suggest that whilst these SNPs are asso-
ciated with probable AD cases (in the GWAS), they do
not strongly relate to SP prevalence, or at all to NFT, in
an autopsy series most representative of the general
population, possibly indicating their complex involve-
ment in the disease.
Abbreviations
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